Clinical trial NCT00657033: Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction
Official title: A Randomized, Double Blind, Parallel Group, Multi-center Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction, and Their Female Partners' Sexual Quality of Life.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Erectile Dysfunction
Keywords: Erectile Dysfunction
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
First posted: 2008-04-14
Enrollment: 229
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.


Eligibility criteria: Inclusion Criteria:

* Males who have had ED for at least six months according to the National Institutes of Health (NIH) Consensus Conference December 7-9, 1992 (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
* Stable, heterosexual relationship for more than 6 months.
* Males 18 years, and older.
* Written informed consent obtained.
* The subject and his female partner must make at least four attempts at sexual intercourse on four separate days during the untreated baseline period (according to the answer to the following question in the Patient Diary: "Was sexual activity initiated with the intention of intercourse?").
* At least 50% of attempts at sexual intercourse during the untreated baseline period must be unsuccessful, according to the following questions from the subject diary (at least one question should be answered "No"): "Were you able to achieve at least some erection (some enlargement of the penis)?"; "Were you able to insert your penis in your partner's vagina?"; "Did your erection last long enough for you to have successful intercourse?".

Exclusion Criteria:

A) Previous or current medical conditions:

* Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
* Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) which, in the Investigator's opinion, would significantly impair erectile function.
* Primary hypoactive sexual desire.
* Spinal cord injury.
* History of surgical prostatectomy (excluding TURP).
* Retinitis pigmentosa.
* Unstable angina pectoris.
* History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months.
* Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate \&#8805; 100 bpm).
* Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
* Clinically significant chronic haematological disease which may lead to priapism such as sickle cell anemia and leukemia.
* Bleeding disorder.
* Significant active peptic ulcer disease.
* Resting hypotension (a resting systolic blood pressure of \< 90 mm Hg) or hypertension (a resting systolic blood pressure \> 170 mm Hg or a resting diastolic blood pressure \> 110 mm Hg).
* History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).
* NYHA Class III and IV heart failure.
* History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
* Symptomatic postural hypotension within 6 months of visit 1.

B) Concomitant medication:

* Subjects who are taking nitrates or nitric oxide donors.
* Subjects who take anticoagulants, except for antiplatelet agents.
* Subjects who are taking androgens.
* Subjects who are taking anti-androgens.
* Subjects who are taking the following inhibitors of cytochrome P450 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
* Subjects who have received any investigational drug (including placebo) within 30 days of Visit 1.
* Use of any treatment for ED within 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
* Subjects who are taking alpha blockers

C) Abnormal laboratory values:

* Subjects who have a serum total testosterone level more than 25% below the age-adjusted lower limit of normal according to the range of the testing laboratory.
* Subjects with a serum creatinine \> 3.0 mg/dl.
* Elevation of AST and/or ALT \> 3 times the upper limit of normal.
* Diabetic subjects with an HbA1c\>12%.

D) Other Exclusion Criteria:

* Subjects age 65 or older who in the judgment of the investigator can not be started on a 10 mg dose
* Subjects with a history of unresponsiveness to any PDE 5 Inhibitor treatment due to lack of efficacy or significant side effects leading to discontinuation of the PDE 5 Inhibitor treatment.
* Subjects unwilling to cease use of vacuum devices, intracavernosal injections, Viagra® or other therapy for ED during the study.
* Unwillingness of the subject or his partner to make 4 attempts at sexual intercourse on four separate days during the untreated baseline period.
* Subjects with known hypersensitivity to Vardenafil, Bay 38-9456 (also known as SB-782528) or any component of the investigational medication.
* Subjects who are illiterate or unable to understand the questionnaires or the Patient Diary.
* Partners who are illiterate or unable to understand the questionnaires.
* Subjects who are unwilling or unable to complete the Patient Diary.
* Subjects or partners who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures.
* Subjects unwilling to refrain from consuming grapefruit juice or products containing grapefruit juice with study medication (Canada only).

Primary outcomes:
measure: The primary measures of efficacy in this study will be improved success of erection maintenance in men with ED and improvement in female partner's sexual quality of life.
timeFrame: Weeks 0 -12
Secondary outcomes:
measure: SEP3 at weeks 4 and 12 of treatment compared to placebo.
timeFrame: Weeks 4 and 12
measure: Additional Patient Diary questions at 4 weeks, 8 weeks, 12 weeks, LOCF, and over entire treatment period compared to placebo. Per-subject success rates will be calculated as the number of successes divided by the number of sexual attempts with a resp
timeFrame: Weeks 4, 8 and 12
measure: Global assessment question (GAQ) at weeks 4 and 12 of treatment compared to placebo
timeFrame: Weeks 4 and 12
measure: Global confidence question (GCQ) at 12 weeks of treatment compared to placebo.
timeFrame: Week 12
measure: The score for the IIEF questionnaire EF domain (IIEF-EF) at weeks 4, 12, and LOCF of treatment compared to placebo
timeFrame: Weeks 4 and 12
measure: Scores from the Treatment Satisfaction Scale (TSS) -- Subject Active Medication module at week 12 and LOCF of treatment compared to placebo. The TSS is a self-report measure of subject and partner's satisfaction with various aspects of erectile function
timeFrame: Week 12
measure: Scores from the mSLQQ-QOL at week 12 and LOCF of treatment compared to placebo
timeFrame: Week 12
measure: Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25) at week 12 of treatment compared to placebo.
timeFrame: Week 12
Other outcomes:
Locations:
city: Phoenix
country: United States
state: Arizona
city: Beverly Hills
country: United States
state: California
city: Irvine
country: United States
state: California
city: Newport Beach
country: United States
state: California
city: San Bernardino
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Diego
country: United States
state: California
city: Trumbull
country: United States
state: Connecticut
city: Jacksonville
country: United States
state: Florida
city: Riverdale
country: United States
state: Georgia
city: Greenbelt
country: United States
state: Maryland
city: Lutherville
country: United States
state: Maryland
city: Lawrenceville
country: United States
state: New Jersey
city: New Brunswick
country: United States
state: New Jersey
city: New York
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Statesville
country: United States
state: North Carolina
city: Wilmington
country: United States
state: North Carolina
city: Calgary
country: Canada
state: Alberta
city: Barrie
country: Canada
state: Ontario
city: Burlington
country: Canada
state: Ontario
city: Kitchener
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: Oakville
country: Canada
state: Ontario
city: Saskatoon
country: Canada
state: Saskatchewan
city: Victoria
country: Canada
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: